Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629505 | 1.00 | MAPT (0.48) | MAPTMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL1273130 | 1.00 | MAPT (0.48) | MAPTMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL9298448 | 0.84 | GAA (0.51) | MAPTMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL13662396 | 0.84 | MAPT (0.46) | MAPTMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL2549625 | 0.84 | GAA (0.51) | MAPTMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL3858960 | 0.84 | GAA (0.51) | MAPTMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL636993 | 0.84 | MAPT (0.46) | MAPTMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL6838857 | 0.84 | KMT2A (0.42) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL13477 | 0.84 | MAPT (0.45) | MAPTMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL6822490 | 0.84 | KMT2A (0.42) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268285-B1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2083844-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8591878-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| US-8377874-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377874-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8314062-B2 | Macrocyclic compounds as antiviral agents | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2012-11-20 | — | — | US | disclosed |
| US-20120196839-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC. (US) | 2012-08-02 | — | — | US | disclosed |
| EP-2041159-B8 | MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ANGELETTI P IST RICHERCHE BIO (IT) | 2012-02-22 | — | — | EP | disclosed |
| EP-2041159-B1 | MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ANGELETTI P IST RICHERCHE BIO (IT) | 2011-09-28 | — | — | EP | disclosed |
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-01-06 | — | — | US | disclosed |
| EP-2083844-A2 | HCV NS3 PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-2041159-A1 | MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008057208-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2007148135-A1 | MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-12-27 | — | — | WO | disclosed |
| US-4964896-A | GAMETOCIDES | MONSANTO COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
| US-4936904-A | Aryl-4-oxonicotinates useful for inducing male sterility in cereal grain plants | MONSANTO TECHNOLOGY LLC | 1990-06-26 | — | — | US | disclosed |
| US-4714492-A | HYBRIDIZATION AGENTS | ROHM AND HAAS COMPANY (US) | 1987-12-22 | — | — | US | disclosed |
| EP-0040082-B1 | NOVEL SUBSTITUTED OXONICOTINATES, THEIR USE AS PLANT GROWTH REGULATORS AND PLANT GROWTH REGULATING COMPOSITIONS CONTAINING THEM | ROHM AND HAAS COMPANY (US) | 1984-04-25 | — | — | EP | disclosed |
| EP-0040082-A1 | Novel substituted oxonicotinates, their use as plant growth regulators and plant growth regulating compositions containing them | ROHM AND HAAS COMPANY (US) | 1981-11-18 | — | — | EP | disclosed |
| US-3932436-A | 2-Thiazolone-5-carboxylic acid ester fungicidal agents | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196839-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | MAPT 3775/4885MEN1 2286/4885KMT2A 2185/4885 |
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | RRP1B, ZC3HAV1, RNASE1 | MAPT 4169/4885MEN1 3427/4885KMT2A 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.